NKGen Biotech (NYSE:NKGN) Trading Down 0.3% – Here’s Why

Shares of NKGen Biotech, Inc. (NYSE:NKGN) fell 0.3% on Friday . The stock traded as low as $0.50 and last traded at $0.53. Approximately 340,069 shares traded hands during trading, a decline of 94% from the average session volume of 5,615,834 shares. The stock had previously closed at $0.54.

NKGen Biotech Price Performance

The stock has a fifty day simple moving average of $0.56 and a 200-day simple moving average of $0.51. The company has a market capitalization of $23.98 million, a price-to-earnings ratio of -0.11 and a beta of 0.48.

Hedge Funds Weigh In On NKGen Biotech

Large investors have recently made changes to their positions in the company. Geode Capital Management LLC grew its position in NKGen Biotech by 12.8% during the fourth quarter. Geode Capital Management LLC now owns 127,168 shares of the company’s stock valued at $83,000 after buying an additional 14,454 shares during the period. Advisory Research Inc. acquired a new stake in shares of NKGen Biotech during the 4th quarter valued at about $28,000. Sequoia Financial Advisors LLC grew its position in shares of NKGen Biotech by 126.1% during the 4th quarter. Sequoia Financial Advisors LLC now owns 156,000 shares of the company’s stock valued at $102,000 after acquiring an additional 87,000 shares during the period. Polar Asset Management Partners Inc. increased its stake in shares of NKGen Biotech by 9.4% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 1,181,872 shares of the company’s stock valued at $447,000 after purchasing an additional 101,872 shares in the last quarter. Finally, Kepos Capital LP acquired a new position in NKGen Biotech in the 4th quarter worth about $151,000. 76.17% of the stock is currently owned by institutional investors and hedge funds.

About NKGen Biotech

NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.